MMP9 and cancer: Isoliquiritigenin (25–50 μM) treatment inhibited signaling molecules such as NF‐κB, P13K/Akt, and p38, decreasing MMP‐2, MMP‐9, VEGF, and HIF‐1α expressions leading to reduce the motility of MDA‐MB‐231 cancer cells.137